Patent intelligence · US
US 11026920
Use of NK-1 receptor antagonist serlopitant in pruritus
Use of NK-1 receptor antagonist serlopitant in pruritus
Patent details — US 11026920
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 8, 2021
- Expiration
- Jun 3, 2041
- Applicant
- Vyne Therapeutics Inc.
- Claims
- 20
- CPC classes
- A61K, A61K31/403, A61K31/4035, A61K45/06
Quick answer
US 11026920 (Use of NK-1 receptor antagonist serlopitant in pruritus) is held by Vyne Therapeutics Inc.. Status: granted. Granted Jun 8, 2021. Expires Jun 3, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Vyne Therapeutics Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/403, A61K31/4035, A61K45/06, A61K47/10, A61K9/0014
More from Vyne Therapeutics Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11433025
Oil foamable carriers and formulations
granted -
US 11219631
Foamable compositions, breakable foams and their uses
granted -
US 11103454
Wax foamable vehicle and pharmaceutical compositions thereof
granted -
US 11033491
Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
granted -
US 10967063
Surfactant-free, water-free formable composition and breakable foams and their uses
granted -
US 10946101
Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
granted
Frequently asked questions
What is US patent 11026920?
US 11026920 (Use of NK-1 receptor antagonist serlopitant in pruritus) is held by Vyne Therapeutics Inc.. Status: granted. Granted Jun 8, 2021. Expires Jun 3, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11026920?
Vyne Therapeutics Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 11026920 expire?
Our index shows an expiration date of Jun 3, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.